Quantitative Evaluation of Muscle Stiffness in Neurological Patients With Muscle Overactivity

Reliability, Validity, and Responsiveness of Shearwave Elastography to Assess Muscle Stiffness in Neurological Population With Muscle Overacivity

Objective:

  1. to investigate reliability, validity and responsiveness of shearwave elastography (SWE) to assess muscle stiffness of overactive upper or lower limb muscles in different angle joint positions in patients with neurological condition
  2. to investigate the relationship between muscle stiffness measured by SWE and by MyotonPro
  3. to investigate the correlation between muscle stiffness measured by SWE and clinical outcomes

Methods: each patient will be assessed three times: two times at an interval of 15 minutes on the same day and one time at an interval of one week at the same time of the day. The following measurements will be made at each evaluation: SWE, MyotonPro, clinical evaluation. SWE and MytotonPro will be taken at different angle joint position.

Outcomes: muscle stiffness measured by SWE and MyotonPro at different angle joint positions, and clinical evaluation (passive range of motion, modified ashworth scale, tardieu scale, fuglmeyer) Hypothesis: SWE is a valid, reliable, and resposive method to assess muscle stiffness in neurological population with muscle overactivity. The results of SWE will be correlated with the results of MyotonPro and with clinical outcomes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Brussels, Belgium, 1200
        • Cliniques universitaires Saint-Luc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 99 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

In- or outpatients of the physical rehabilitation unit of the Cliniques universitaires Saint-Luc

Description

Inclusion Criteria:

  • age > 18 years
  • hemiparesia/-plegia following neurological condition (TBI, stroke,...)
  • > 3 months after injury
  • muscle overactivity in lower limb

Exclusion Criteria:

  • other neurological or orthopaedic conditions involving the affected limb
  • aphasia or major cognitive impairment limiting functional assessment
  • botulinum toxin injection in the last 3 months
  • previous treatment of muscle overactivity with surgical procedures.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
reliability, validity and responsiveness shearwave elastography (SWE) to assess muscle elasticity
Time Frame: Day 1
expressed in m/s. A smaller shearwave velocity indicates a better outcome.
Day 1
reliability, validity and responsiveness shearwave elastography (SWE) to assess muscle elasticity
Time Frame: Day 1 + 15 minutes
expressed in m/s. A smaller shearwave velocity indicates a better outcome
Day 1 + 15 minutes
reliability, validity and responsiveness shearwave elastography (SWE) to assess muscle elasticity
Time Frame: Day 1 + 7-14 days
expressed in m/s. A smaller shearwave velocity indicates a better outcome
Day 1 + 7-14 days

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
muscle stiffness assessment with MyotonPro
Time Frame: two times day 1 at 15minutes interval + 7-14 days later at same time of the day
a smaller muscle stiffness indicates a better outcome
two times day 1 at 15minutes interval + 7-14 days later at same time of the day

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
passive range of motion
Time Frame: day 1 + 7-14 days later at same time of the day
expressed in angles °. The greater the angle, the better the outcome
day 1 + 7-14 days later at same time of the day
modified ashworth scale
Time Frame: day 1 + 7-14 days later at same time of the day
minimum score:0; maximum score: 4. A higher score indicates a greater spasticity thus a worse outcome
day 1 + 7-14 days later at same time of the day
Tardieu scale
Time Frame: day 1 + 7-14 days later at same time of the day
minimum score:0; maximum score: 4. A higher score indicates a greater spasticity thus a wourse outcome
day 1 + 7-14 days later at same time of the day
Fugl-meyer score (Lower extremity; motor function)
Time Frame: day 1 + 7-14 days later at same time of the day
maximum score of 34. The highest the score, the better the motor function
day 1 + 7-14 days later at same time of the day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Gaetan Stoquart, MD, PhD, Cliniques universitaires Saint-Luc

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2022

Primary Completion (Actual)

May 30, 2023

Study Completion (Actual)

May 30, 2023

Study Registration Dates

First Submitted

August 17, 2022

First Submitted That Met QC Criteria

August 19, 2022

First Posted (Actual)

August 22, 2022

Study Record Updates

Last Update Posted (Estimated)

June 16, 2023

Last Update Submitted That Met QC Criteria

June 15, 2023

Last Verified

June 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe